Autosomal-Recessive Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter Gene SLC39A8.
Boycott KM, Beaulieu CL, Kernohan KD, Gebril OH, Mhanni A, Chudley AE, Redl D, Qin W, Hampson S, Küry S, Tetreault M, Puffenberger EG, Scott JN, Bezieau S, Reis A, Uebe
S, Schumacher J, Hegele RA, McLeod DR, Gálvez-Peralta M, Majewski J, Ramaekers VT; Care4Rare Canada Consortium, Nebert DW, Innes AM, Parboosingh JS, Abou Jamra R.
Am J Hum Genet. 2015 Dec 3;97(6):886-93. doi: 10.1016/j.ajhg.2015.11.002. PMID: 26637978
Comparing gene expression during cadmium uptake and distribution: untreated versus oral Cd-treated wild-type and ZIP14 knockout mice.
Jorge-Nebert LF, Gálvez-Peralta M, Landero Figueroa J, Somarathna M, Hojyo S, Fukada T, Nebert DW.
Toxicol Sci. 2015 Jan;143(1):26-35. doi: 10.1093/toxsci/kfu204. Epub 2014 Oct 7. PMID: 25294218
Tissue-Specific Induction of Mouse ZIP8 and ZIP14 Divalent Cation/Bicarbonate Symporters by, and Cytokine Response to, Inflammatory Signals.
Gálvez-Peralta M, Wang Z, Bao S, Knoell DL, Nebert DW.
Int J Toxicol. 2014 Apr 10;33(3):246-258. [Epub ahead of print] PMID: 24728862
Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.
Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH.
Mol Pharmacol. 2014 May;85(5):723-34. doi: 10.1124/mol.113.088674. Epub 2014 Feb 25. PMID: 24569089
Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways.
Divanovic S, Dalli J, Jorge-Nebert LF, Flick LM, Gálvez-Peralta M, Boespflug ND, Stankiewicz TE, Fitzgerald JM, Somarathna M, Karp CL, Serhan CN, Nebert DW.
J Immunol. 2013 Sep 15;191(6):3347-57. doi: 10.4049/jimmunol.1300699. Epub 2013 Aug 16. PMID: 23956430
Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences--Cyp1 knockout mouse lines as a paradigm.
Nebert DW, Shi Z, Gálvez-Peralta M, Uno S, Dragin N.
Mol Pharmacol. 2013 Sep;84(3):304-13. doi: 10.1124/mol.113.086637. Epub 2013 Jun 12. Review. PMID: 23761301
ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB.
Liu MJ, Bao S, Gálvez-Peralta M, Pyle CJ, Rudawsky AC, Pavlovicz RE, Killilea DW, Li C, Nebert DW, Wewers MD, Knoell DL.
Cell Rep. 2013 Feb 21;3(2):386-400. doi: 10.1016/j.celrep.2013.01.009. Epub 2013 Feb 9. PMID: 2340329
ZIP14 and ZIP8 zinc/bicarbonate symporters in Xenopus oocytes: characterization of metal uptake and inhibition.
Nebert DW, Gálvez-Peralta M, Hay EB, Li H, Johansson E, Yin C, Wang B, He L, Soleimani M.
Metallomics. 2012 Nov;4(11):1218-25. doi: 10.1039/c2mt20177a. Epub 2012 Oct 22. PMID: 23090441
Oral benzo[a]pyrene in Cyp1a1/1b1(-/-) double-knockout mice: Microarray analysis during squamous cell carcinoma formation in preputial gland duct.
Gálvez-Peralta M, Shi Z, Chen J, Miller ML, Nebert DW.
Int J Cancer. 2013 May 1;132(9):2065-75. doi: 10.1002/ijc.27897. Epub 2012 Dec 4. PMID: 23047765
ZIP8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in utero.
Gálvez-Peralta M, He L, Jorge-Nebert LF, Wang B, Miller ML, Eppert BL, Afton S, Nebert DW.
PLoS One. 2012;7(5):e36055. doi: 10.1371/journal.pone.0036055. Epub 2012 May 1. PMID: 22563477
About Marina Galvez Peralta
Dr. Marina Galvez, is an Assistant Professor in the Department of Pharmaceutical Sciences at the West Virginia University School of Pharmacy. She is a PharmD, MS, PhD and Board Certified Clinical Pharmacologist. Dr. Galvez’s areas of research interest are understanding chemotherapy resistance, individual response variability to chemotherapy, drug combination optimization and drug response in special populations. Her expertise includes drug discovery, combinatorial pharmacotherapy, molecular pharmacology, metal toxicity, pharmacogenomics and teratogenicity. She is currently involved in coordinating or teaching different integrated courses at the School of Pharmacy at WVU (Pharmacogenomics, Drug Delivery, Immunology, Cardiology, and Oncology among others), as well as the area of emphasis on research for the PharmD program. After receiving her PharmD and PhD at the University of Seville in Spain, she completed postdoctoral fellowships at Mayo Clinic and the University of Cincinnati and obtained PharmD equivalency in the States. Dr. Galvez has also taught in Pharmacognosy, Pharmacodynamics, Phytotherapy and Toxicology courses in the past. Dr. Galvez has authored over 25 manuscripts and her work has been cited in more than 400 articles. In addition, she serves as treasurer of the AWIS-WV chapter, and as mentor for the WVU chapter of the American Association of Pharmaceutical Scientists.